These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25316678)

  • 21. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
    Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
    J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.
    Somervaille TC; Cleary ML
    Cancer Cell; 2006 Oct; 10(4):257-68. PubMed ID: 17045204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
    Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
    Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
    Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
    J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
    Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
    Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
    Abdul-Nabi AM; Yassin ER; Varghese N; Deshmukh H; Yaseen NR
    PLoS One; 2010 Aug; 5(8):e12464. PubMed ID: 20805992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK1 is required for the development of NRAS-driven leukemia.
    Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
    Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
    Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
    Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
    Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia.
    Weisberg SP; Smith-Raska MR; Esquilin JM; Zhang J; Arenzana TL; Lau CM; Churchill M; Pan H; Klinakis A; Dixon JE; Mirny LA; Mukherjee S; Reizis B
    Cell Rep; 2014 Feb; 6(3):528-40. PubMed ID: 24485662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.